HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antigingivitis product warnings for periodontitis symptoms advised by FDA group.

This article was originally published in The Rose Sheet

Executive Summary

ANTIGINGIVITIS PRODUCT LABEL WARNING FOR SIGNS OF PERIODONTITIS RECOMMENDED by FDA's Dental Plaque Subcommittee during its meeting in Gaithersburg, Md. May 28. The product warning suggested by the advisory group states: "See your dentist immediately before use if you have pain or swelling of the gums, pus from the gumline, loose teeth or increased spacing between teeth. These signs or symptoms may be a sign of periodontitis, a more serious form of gum disease." The subcommittee also agreed a warning should be included on labeling for antigingivitis dentifrices that states: "If gingivitis, redness or bleeding persist for more than two weeks, see your dentist." Exact wording of the warnings may be changed to fit with FDA's proposed revisions to the OTC label format, the subcommittee noted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel